SCHEMBL9105929

SCHEMBL9105929

COc1cc(CC(=O)c2cccnc2)c(NC(=O)O)cc1Cl

nearest known ligand 0.55

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 2/20 0.50
MAPT P10636 5/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
POLB P06746 1/20 0.46
TSHR P16473 1/20 0.46
LMNA P02545 1/20 0.45
KDM4E B2RXH2 5/20 0.45
GAA P10253 3/20 0.45
MEN1 O00255 3/20 0.45
KMT2A Q03164 3/20 0.45
ALDH1A1 P00352 3/20 0.44
PLOD2 O00469 1/20 0.43
CHEK1 O14757 2/20 0.43
NPC1 O15118 1/20 0.42
RAB9A P51151 1/20 0.42
PSMD14 O00487 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9105339 0.78 KMT2A (0.45) MAPTSMN1; SMN2LMNAKDM4EGAA
SCHEMBL9103819 0.78 LMNA (0.42) MAPTSMN1; SMN2LMNAKDM4EGAA
SCHEMBL6117614 0.78 MAPK1 (0.42) MAPK1MAPTSMN1; SMN2POLBTSHR
SCHEMBL3450804 0.75 MAPK1 (0.55) MAPK1MAPTTSHRLMNAGAA
SCHEMBL4568367 0.71 MEN1 (0.43) MAPK1MAPTSMN1; SMN2POLBTSHR
SCHEMBL15998675 0.70 TSHR (0.53) MAPTSMN1; SMN2POLBTSHRKDM4E
SCHEMBL838608 0.70 PLOD2 (0.57) MAPK1MAPTSMN1; SMN2LMNAKDM4E
SCHEMBL10882130 0.69 MAPK1 (0.65) MAPK1MAPTSMN1; SMN2POLBLMNA
SCHEMBL838069 0.69 ALDH1A1 (0.53) MAPTSMN1; SMN2POLBTSHRLMNA
SCHEMBL4324973 0.69 KDM4E (0.68) MAPTSMN1; SMN2POLBLMNAKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8815903-B2 Indole derivative and pharmacologically acceptable salt thereof KISSEI PHARMACEUTICAL CO., LTD. (JP) 2014-08-26 US disclosed
EP-2669272-A1 INDOLE DERIVATIVE AND PHARMACOLOGICALLY ACCEPTABLE SALT OF SAME Kissei Pharmaceutical Co., Ltd. (JP) 2013-12-04 EP disclosed
US-20130317065-A1 INDOLE DERIVATIVE AND PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF KISSEI PHARMACEUTICAL COMPANY, LIMITED (JP) 2013-11-28 US disclosed
EP-2460791-A1 INDOLE DERIVATIVE AND PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF Kissei Pharmaceutical Co., Ltd. (JP) 2012-06-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130317065-A1 INDOLE DERIVATIVE AND PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF PTGER1, CYSLTR1, LTB4R MAPK1 660/4885MAPT 3362/4885SMN1; SMN2 4793/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.